Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 15, 2013. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 664,000 Ordinary Shares of 25 pence each.
- Purchase Date: August 15, 2013.
- Price Range: Highest price paid was 1,674.50 pence per share; lowest price paid was 1,646.00 pence per share.
- Treasury Holdings (Settled): 509,460,412 shares (9.41% of total issued share capital).
- Treasury Holdings (Including Unsettled): 510,569,412 shares (10.41% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,903,493,212 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 664,000 shares. Consequently, the percentage of total voting rights held in treasury increased to 10.41% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, or contingencies. It states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (509,460,412 settled) against the company's latest annual report.
- Confirm the total issued share capital to validate the 9.41% treasury ownership calculation.
- Check the status of the 1,109,000 shares purchased but not yet settled to confirm final treasury totals.
- Review the remaining authorization for share buybacks under the May 1, 2013 shareholder mandate.